pyrazines has been researched along with Bone Loss, Osteoclastic in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 14 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, B; Hu, YQ; Huang, Q; Jie, Q; Li, XJ; Lu, WG; Luo, ZJ; Shi, J; Wang, L; Xu, XL; Yang, L; Zhang, HY | 1 |
| Choi, SY; Kim, HJ; Kim, JY; Kim, YG; Kwon, TG; Lee, HJ; Lee, JH; Lee, Y; Pokhrel, NK | 1 |
| Eriksson, E; Sävendahl, L; Zaman, F | 1 |
| Horton, T; Hunger, SP | 1 |
| Bakhous, A; Waheed, S; Zhu, H | 1 |
| Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Gkotzamanidou, M; Kanellias, N; Kastritis, E; Manios, E; Migkou, M; Papadimitriou, C; Roussou, M; Terpos, E | 1 |
| Baerts, L; Behets, GJ; D'Haese, PC; De Meester, I; Glorie, L; Verhulst, A | 1 |
| Anderson, KC; Breitkreutz, I; Chauhan, D; Hideshima, T; Mitsiades, C; Munshi, NC; Okawa, Y; Raab, MS; Raje, N; Richardson, PG; Vallet, S | 1 |
| Terpos, E | 1 |
| Hata, K; Ikeda, F; Matsubara, T; Nakanishi, M; Nishimura, R; Okada, M; Yasuda, H; Yoneda, T | 1 |
| Baum, W; Distler, JH; Frey, B; Gückel, E; Meister, S; Neubert, K; Polzer, K; Schett, G; Voll, RE; Zwerina, J | 1 |
| Kupisiewicz, K | 1 |
| Bao, L; Huang, XJ; Lai, YY; Lu, J; Lu, XJ; Zhang, XH; Zhu, HH | 1 |
| Li, Z; Liu, M; Liu, T; Luo, J; Qiu, WW; Tang, J; Xu, J; Yang, F | 1 |
| Blanco, JF; Collins, L; Garayoa, M; Garcia-Gomez, A; Hornick, MC; Hurchla, MA; Kirk, CJ; Li, A; Ocio, EM; Pandiella, A; Piwnica-Worms, D; San Miguel, JF; Tomasson, MH; Vij, R; Weilbaecher, KN | 1 |
| Askov-Hansen, C; Hartmann, B; Henriksen, DB; Holst, JJ; Jeppesen, PB; Lund, P | 1 |
| Roodman, GD | 1 |
| Berenson, JR | 1 |
| Fleissner, C; Hecht, M; Heider, U; Jakob, C; Kaiser, M; Kleeberg, L; Krebbel, H; Manz, RA; Mieth, M; Sezer, O; Sterz, J; von Metzler, I | 1 |
| Andersen, TL; Boissy, P; Delaissé, JM; Kupisiewicz, K; Lund, T; Plesner, T | 1 |
2 review(s) available for pyrazines and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Topics: Antineoplastic Agents, Phytogenic; Bone and Bones; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Calcium-Binding Proteins; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Multiple Myeloma; Osteoblasts; Osteoclasts; Protease Inhibitors; Pyrazines; Resveratrol; Signal Transduction; Stilbenes; Wnt Proteins | 2011 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid | 2002 |
1 trial(s) available for pyrazines and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Topics: Antineoplastic Agents; B-Cell Activating Factor; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Cathepsin K; Cathepsins; Cells, Cultured; Chemokine CCL3; Humans; Integrin alphaVbeta3; Lenalidomide; Multiple Myeloma; Osteoclasts; Osteoprotegerin; Proto-Oncogene Proteins; Pyrazines; RANK Ligand; Thalidomide; Trans-Activators; Transcription Factor AP-1; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2008 |
17 other study(ies) available for pyrazines and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Anti‑osteoporotic effects of tetramethylpyrazine via promoting osteogenic differentiation and inhibiting osteoclast formation.
Topics: Animals; Bone and Bones; Bone Resorption; Cell Differentiation; Female; Interleukin-6; Osteoblasts; Osteoclasts; Osteogenesis; Pyrazines; RANK Ligand; Rats; Tomography, X-Ray Computed | 2017 |
A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption.
Topics: Agammaglobulinaemia Tyrosine Kinase; Alveolar Bone Loss; Animals; Benzamides; Bone Marrow Cells; Bone Resorption; Cell Differentiation; Lipopolysaccharides; Mice; NFATC Transcription Factors; Osteoclasts; Porphyromonas gingivalis; Pyrazines; RANK Ligand | 2019 |
Bortezomib and bone health in adults: can we extend these findings to children?
Topics: Adult; Animals; Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Humans; Infant; Male; Mice; Multiple Myeloma; Pyrazines | 2013 |
Children are not large mice.
Topics: Adolescent; Animals; Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Child; Child, Preschool; Chondrocytes; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Infant; Mice; Pyrazines | 2013 |
Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Melphalan; Middle Aged; Multimodal Imaging; Osteolysis; Positron-Emission Tomography; Pyrazines; Recurrence; Remission Induction; Rituximab; Tomography, X-Ray Computed; Waldenstrom Macroglobulinemia; Zoledronic Acid | 2013 |
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Pyrazines; Serum Response Element; Thalidomide; Transplantation, Autologous | 2014 |
DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats.
Topics: Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Compressive Strength; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Male; Pyrazines; Rats; Rats, Wistar; Sitagliptin Phosphate; Streptozocin; Stress, Mechanical; Triazoles | 2014 |
Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
Topics: Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; Osteoclasts; Pulse Therapy, Drug; Pyrazines | 2008 |
Cbp recruitment of Csk into lipid rafts is critical to c-Src kinase activity and bone resorption in osteoclasts.
Topics: Actins; Animals; Apoptosis; Bone Resorption; Cell Differentiation; Cell Line; CSK Tyrosine-Protein Kinase; Hydrazines; Macrophages; Membrane Microdomains; Membrane Proteins; Mice; Osteoclasts; Phosphoproteins; Protein-Tyrosine Kinases; Pyrazines; Quinolines; Signal Transduction; src-Family Kinases | 2010 |
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
Topics: Animals; Arthritis; Bone and Bones; Bone Resorption; Boronic Acids; Bortezomib; Cartilage, Articular; Chronic Disease; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Osteoclasts; Osteoprotegerin; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; RANK Ligand; Synovial Membrane; Tumor Necrosis Factor-alpha | 2011 |
[Effect of different regimens on bone disease of multiple myeloma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multiple Myeloma; Pyrazines; RANK Ligand; Thalidomide | 2011 |
Synthesis and biological evaluation of heterocyclic ring-fused betulinic acid derivatives as novel inhibitors of osteoclast differentiation and bone resorption.
Topics: Acid Phosphatase; Animals; Betulinic Acid; Bone Density Conservation Agents; Bone Resorption; Cathepsin K; Cell Differentiation; Cell Line; Cell Proliferation; Crystallography, X-Ray; Female; Isoenzymes; Isoxazoles; Mice; Mice, Inbred C57BL; Osteoclasts; Ovariectomy; Pentacyclic Triterpenes; Pyrazines; Pyrazoles; Pyrimidines; RANK Ligand; Rats; Structure-Activity Relationship; Tartrate-Resistant Acid Phosphatase; Thiazoles; Triterpenes | 2012 |
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Calcification, Physiologic; Cell Differentiation; Cell Proliferation; Epoxy Compounds; Humans; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Oligopeptides; Osteoblasts; Osteoclasts; Osteogenesis; Proteasome Inhibitors; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure.
Topics: Adult; Area Under Curve; Biomarkers; Bone Resorption; Collagen Type I; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glucagon-Like Peptide 2; Humans; Injections, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Peptide Fragments; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Role of the bone marrow microenvironment in multiple myeloma.
Topics: Adjuvants, Immunologic; Bone and Bones; Bone Marrow; Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Cell Division; Chemokine CCL3; Chemokine CCL4; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Macrophage Inflammatory Proteins; Membrane Glycoproteins; Multiple Myeloma; Osteoclasts; Osteolysis; Osteoprotegerin; Protease Inhibitors; Protein Prenylation; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Bortezomib inhibits human osteoclastogenesis.
Topics: Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Cell Differentiation; Cell Lineage; Female; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Male; Multiple Myeloma; NF-kappa B; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Pyrazines; Pyridines; RANK Ligand; Signal Transduction; Stem Cells; Transcription Factor AP-1; Vascular Endothelial Growth Factor A | 2007 |
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Topics: Antineoplastic Agents; Bone Resorption; Boronic Acids; Bortezomib; Cell Nucleus; Cell Proliferation; Humans; Multiple Myeloma; NF-kappa B; Osteoblasts; Osteoclasts; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2008 |